Comparative Pharmacology
Head-to-head clinical analysis: ACCOLATE versus MONTELUKAST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCOLATE versus MONTELUKAST.
ACCOLATE vs Montelukast
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective leukotriene receptor antagonist (LTRA) that inhibits the cysteinyl leukotriene (CysLT1) receptor, preventing bronchoconstriction, inflammation, and airway edema.
Selective leukotriene receptor antagonist that inhibits the cysteinyl leukotriene (CysLT1) receptor, thereby reducing airway edema, smooth muscle contraction, and inflammatory cell infiltration.
20 mg orally twice daily, 1 hour before or 2 hours after meals.
10 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is 10–20 hours (mean ~15 hours) in healthy adults; prolonged in hepatic impairment.
Clinical Note
moderateMontelukast + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Montelukast."
Clinical Note
moderateMontelukast + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Montelukast."
Clinical Note
moderateMontelukast + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Montelukast."
Clinical Note
moderateMontelukast + Fluconazole
Terminal elimination half-life is 2.7–5.5 hours in healthy adults. No significant accumulation with once-daily dosing.
Primarily hepatic metabolism via CYP2C9; 87% excreted in feces, 10% in urine as metabolites. Less than 1% excreted unchanged.
Primarily hepatic metabolism (CYP3A4, 2C8, 2C9); excreted in bile and feces (~86%), renal excretion of parent drug and metabolites is minimal (<0.2% unchanged).
Category C
Category C
Leukotriene Receptor Antagonist
Leukotriene Receptor Antagonist
"The metabolism of Fluconazole can be decreased when combined with Montelukast."